{"entity":{"id":"avzo-1418","kind":"drug","name":"AVZO-1418","aka":["DB-1418","AVZO-1418/DB-1418"],"tldr":"AVZO-1418 is an experimental antibody-drug conjugate that targets two proteins, EGFR and HER3, on cancer cells. Avenzo Therapeutics licensed it from DualityBio and is testing it in a first phase 1/2 trial in advanced solid tumours.","summary":"AVZO-1418, also called DB-1418, is an antibody-drug conjugate that binds two targets, EGFR and HER3, and carries a topoisomerase I inhibitor payload; DualityBio built it on its Duality Innovative Bispecific Antibody Conjugate (DIBAC) platform. Avenzo Therapeutics and DualityBio announced an exclusive licence on 7 January 2025 giving Avenzo rights outside Greater China, with USD 50 million upfront and up to about USD 1.15 billion in milestones; at that point the drug was in studies before human testing. AVENTINE-1 (NCT07038343), sponsored by Avenzo with DualityBio as collaborator, is a phase 1/2 trial that started in June 2025 in locally advanced or metastatic epithelial solid tumours, with the drug given alone and possibly with other medicines. No results are recorded here.","status":"phase-2","asOf":"2026-11-03","links":[{"label":"Avenzo and DualityBio licence announcement, 7 January 2025 (BioSpace copy)","url":"https://www.biospace.com/press-releases/avenzo-therapeutics-and-dualitybio-announce-exclusive-global-license-for-potential-best-in-class-egfr-her3-antibody-drug-conjugate"},{"label":"ClinicalTrials.gov: AVENTINE-1 (NCT07038343)","url":"https://clinicaltrials.gov/study/NCT07038343"}],"tags":["pipeline","deal-asset"],"related":[],"cancers":["nsclc","cholangiocarcinoma","urothelial"],"sections":[],"technologies":["adc","topoisomerase-inhibitors","bispecific-antibody"],"targets":["egfr","her3"],"drugs":[],"companies":["avenzo","dualitybio"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07038343"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit (ClinicalTrials.gov v2 + company press releases)","editedOn":"2026-11-03"},"code":"DB-1418","modality":"Bispecific antibody-drug conjugate (EGFR x HER3, topoisomerase I inhibitor payload)","mechanism":"An antibody that binds both EGFR and HER3 on cancer cells carries a topoisomerase I inhibitor, a chemotherapy that breaks DNA, into those cells. It was built on DualityBio's DIBAC bispecific conjugate platform.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/avzo-1418/","neighbours":{"cancer":[{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"},{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"target":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"},{"id":"her3","kind":"target","name":"HER3","route":"/targets/her3/"}],"company":[{"id":"avenzo","kind":"company","name":"Avenzo Therapeutics","route":"/companies/avenzo/"},{"id":"dualitybio","kind":"company","name":"Duality Biotherapeutics","route":"/companies/dualitybio/"}],"trial":[{"id":"nct07038343","kind":"trial","name":"AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)","route":"/trials/nct07038343/"}]}}